Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.

@article{Sano1992DoubleblindPD,
  title={Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.},
  author={M. Sano and K. Bell and L. C{\^o}t{\'e} and G. Dooneief and A. Lawton and L. Legler and K. Marder and A. Naini and Y. Stern and R. Mayeux},
  journal={Archives of neurology},
  year={1992},
  volume={49 11},
  pages={
          1137-41
        }
}
  • M. Sano, K. Bell, +7 authors R. Mayeux
  • Published 1992
  • Psychology, Medicine
  • Archives of neurology
  • Acetyl levocarnitine hydrochloride has been reported to retard dementia in patients with Alzheimer's disease. In a double-blind, parallel design, placebo-controlled pilot study of 30 mild to moderately demented patients with probable Alzheimer's disease, tests of memory, attention, language, visuospatial, and constructional abilities were administered, and the level of acetyl levocarnitine was measured in the cerebrospinal fluid. Patients were then randomly assigned to receive acetyl… CONTINUE READING
    81 Citations

    Paper Mentions

    Acetyl-L-carnitine for dementia.
    • 81

    References

    SHOWING 1-10 OF 22 REFERENCES
    Effects of oral physostigmine in Alzheimer's disease
    • 81
    Pathological brain ageing: evaluation of the efficacy of a pharmacological aid.
    • 4
    Oral physostigmine treatment of patients with Alzheimer's disease.
    • 216
    "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
    • 72,893
    • PDF